Van Herk Group

SkylineDx B.V. is a biotech company based in Rotterdam, the Netherlands, specializing in the development and commercialization of gene signature-based diagnostic tests for personalized medicine in oncology. The company focuses on creating molecular diagnostic tools for blood cancers, including AMLprofiler, which identifies subtypes of Acute Myeloid Leukemia, and MMprofiler, a microarray-based service for Multiple Myeloma that determines clinically relevant subtypes. SkylineDx collaborates with academic, pharmaceutical, and industrial partners to advance companion diagnostics and other testing solutions. The company has established a strategic partnership with the Mayo Clinic to enhance its offerings. Founded in 2005, SkylineDx aims to support healthcare professionals in making informed treatment decisions tailored to individual patients.

SkylineDx B.V. is a biotech company based in Rotterdam, the Netherlands, specializing in the development and commercialization of gene signature-based diagnostic tests for personalized medicine in oncology. The company focuses on creating molecular diagnostic tools for blood cancers, including AMLprofiler, which identifies subtypes of Acute Myeloid Leukemia, and MMprofiler, a microarray-based service for Multiple Myeloma that determines clinically relevant subtypes. SkylineDx collaborates with academic, pharmaceutical, and industrial partners to advance companion diagnostics and other testing solutions. The company has established a strategic partnership with the Mayo Clinic to enhance its offerings. Founded in 2005, SkylineDx aims to support healthcare professionals in making informed treatment decisions tailored to individual patients.

Ceradis B.V. is a company that specializes in the development and marketing of environmentally friendly solutions for plant nutrition and crop protection products. Founded in 2005 and based in Wageningen, the Netherlands, with an additional office in Bogotá, Colombia, Ceradis also offers crop formulation services. The company's products feature patented formulations that ensure optimal activity of ingredients and provide excellent handling characteristics for users. Ceradis serves the agricultural industry both in the Netherlands and on an international scale.

Medis is a provider of post-processing software for the quantification of cardiovascular images. Medis' mission is to empower medical professionals by providing software that gives them the facts.

DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.

Vastned is a retail property company based in the Netherlands that specializes in high-quality retail spaces in prominent locations across Europe. It focuses on investing in prime shopping venues in major cities, specifically targeting the Premium City High Street Shops segment. Vastned's portfolio is valued at approximately €1.5 billion and includes a diverse range of properties, primarily leased to leading international and national retail brands in sectors such as fashion, dining, and general retail. The company operates across various segments, with significant operations in the Netherlands, France, Belgium, and Spain, generating most of its rental income from these key markets.

Sensara B.V., based in Rotterdam, the Netherlands, specializes in home healthcare equipment and software through its product Sensara HomeCare. The company aims to empower senior citizens and vulnerable individuals to maintain their independence while ensuring their safety and well-being. Sensara utilizes self-learning algorithms to monitor medically verified profiles, analyzing data from various sensors and providing alerts, signals, and advice to family members or caregivers as needed. The information is accessible through user-friendly apps and interfaces, allowing clients to have control over their own data and privacy. Sensara's modular product line offers comprehensive solutions that cater to different living environments, from independent and assisted living to nursing homes, with the goal of enhancing care based on historical data.

NightBalance B.V. develops and markets an obstructive sleep apnea (OSA) device for the treatment of positional obstructive sleep apnea to customers in Europe. It develops Sleep Position Trainer (SPT), which measures the sleep behavior of the patient continuously; gives a gentle vibration once the patient turns into the supine position; and reminds the patient to change their sleeping position without disrupting their natural sleeping architecture. The company was founded in 2009 and is based in The Hague, the Netherlands. As of May 8, 2018, NightBalance B.V. operates as a subsidiary of Koninklijke Philips N.V.

VBHC is a professionally managed real estate company with marquee investors. They are privileged that India's largest home financer, Housing Development Finance Corporation (HDFC), is an anchor equity investor in VBHC.

DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.

Isobionics B.V. develops, produces, and sells natural products for customers in flavor and fragrance market. It produces compounds, such as citrus oils that include lemon, orange, and grapefruit; compounds, including valencene and nootkatone, menthol, sandalwood oil, and patchouli oil; and other basic building blocks for the flavor and fragrance industry. The company was founded in 2008 and is based in Geleen, the Netherlands. As of September 26, 2019, Isobionics B.V. operates as a subsidiary of BASF SE.

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

SkylineDx B.V. is a biotech company based in Rotterdam, the Netherlands, specializing in the development and commercialization of gene signature-based diagnostic tests for personalized medicine in oncology. The company focuses on creating molecular diagnostic tools for blood cancers, including AMLprofiler, which identifies subtypes of Acute Myeloid Leukemia, and MMprofiler, a microarray-based service for Multiple Myeloma that determines clinically relevant subtypes. SkylineDx collaborates with academic, pharmaceutical, and industrial partners to advance companion diagnostics and other testing solutions. The company has established a strategic partnership with the Mayo Clinic to enhance its offerings. Founded in 2005, SkylineDx aims to support healthcare professionals in making informed treatment decisions tailored to individual patients.

NightBalance B.V. develops and markets an obstructive sleep apnea (OSA) device for the treatment of positional obstructive sleep apnea to customers in Europe. It develops Sleep Position Trainer (SPT), which measures the sleep behavior of the patient continuously; gives a gentle vibration once the patient turns into the supine position; and reminds the patient to change their sleeping position without disrupting their natural sleeping architecture. The company was founded in 2009 and is based in The Hague, the Netherlands. As of May 8, 2018, NightBalance B.V. operates as a subsidiary of Koninklijke Philips N.V.

Vitalnext B.V., founded in 2013 and based in Amersfoort, the Netherlands, focuses on developing products that provide evidence-based health benefits for the aging population. The company offers a range of products, including Promanna, which comprises orally administered active small molecules; L-Proline, known for its positive effects on organisms under stress; D-Mannitol, a sugar with historical health benefits; and Vital01, designed to address malnutrition in the elderly. Vitalnext aims to enhance healthy aging, responding to the growing global demand for products that promote prolonged well-being. Their most advanced offering is an innovative medical nutrition product that not only helps improve body weight in malnourished individuals but also enhances body composition by increasing muscle mass. The company commercializes its products through distribution and licensing agreements with specialized partners, bridging the gap between life sciences and consumer health products.

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.